What is PacGenomics?
PacGenomics operates as a high-complexity clinical laboratory, specializing in advanced molecular diagnostics and genomic analysis. The company provides a comprehensive suite of services, including infectious disease testing, clinical toxicology, and next-generation sequencing. By integrating liquid chromatography-mass spectrometry with proprietary sequencing workflows, PacGenomics delivers actionable data for healthcare providers and patients alike. Their market position is defined by a focus on precision healthcare, spanning applications from reproductive genetic testing to DNA identity verification. The firm's commitment to data integrity and clinical accuracy serves as a critical differentiator in the competitive diagnostics market, enabling them to support complex medical decision-making processes through reliable, high-throughput laboratory services.
How much funding has PacGenomics raised?
PacGenomics has raised a total of $4.7M across 3 funding rounds:
Private Equity
$1.5M
Private Equity
$3M
Debt
$150K
Private Equity (2013): $1.5M, investors not publicly disclosed
Private Equity (2014): $3M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Key Investors in PacGenomics
PPP
Public-Private Partnership
Undisclosed Investor
An institutional backer that participated in the initial private equity rounds, providing the foundational capital necessary for laboratory development.
Undisclosed Investor
A private equity participant focused on long-term value creation within the clinical diagnostics and biotechnology sectors.
What's next for PacGenomics?
With the recent infusion of $150K, PacGenomics is well-positioned to accelerate its technological roadmap and expand its diagnostic service footprint. The strategic focus will likely center on enhancing its sequencing capabilities and scaling its laboratory throughput to meet the rising demand for personalized medicine. As the company navigates the next phase of its lifecycle, the emphasis will remain on optimizing operational efficiencies and integrating emerging diagnostic technologies. By maintaining its focus on high-standard clinical outcomes, PacGenomics is poised to strengthen its influence in the molecular diagnostics industry, potentially exploring new partnerships or service expansions that leverage its existing infrastructure to address evolving healthcare challenges.
See full PacGenomics company page
